Comparative Pharmacology
Head-to-head clinical analysis: EXFORGE HCT versus RAU SED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXFORGE HCT versus RAU SED.
EXFORGE HCT vs RAU-SED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EXFORGE HCT is a combination of amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and water by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
One tablet orally once daily. Initial dose based on previous antihypertensive therapy; maximum dose is one tablet of 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide per day.
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
None Documented
None Documented
Valsartan: 6 hours (terminal). Amlodipine: 30-50 hours (terminal), permits once-daily dosing. Hydrochlorothiazide: 6-15 hours (terminal).
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
Valsartan: 13% excreted unchanged in urine, 83% in feces via biliary secretion. Amlodipine: 10% excreted unchanged in urine, 60% as metabolites in urine, 20-25% in feces. Hydrochlorothiazide: ≥95% excreted unchanged in urine.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Category C
Category C
Antihypertensive
Antihypertensive